Targeting Lysosomal Thiols for Immunogenic Cancer Cell Death
Angewandte Chemie International Edition · 27.01.2025 · 64 (5)
DOI: 10.1002/anie.202417509 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 19.11.2024. Verfasst von Anton Arkhypov und 6 weiteren Autor:innen. Beteiligte Einrichtung: Friedrich-Alexander-University of Erlangen-Nürnberg (FAU), Department of Chemistry and Pharmacy, Organic Chemistry II, 91058, Erlangen, Germany. Hauptthemen laut MEDLINE: Sulfhydryl Compounds, Lysosomes, Antineoplastic Agents, Immunogenic Cell Death. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: H2020 European Research Council, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
The number and stability of lysosomes (LYs) are different in cancer and healthy cells that makes them a possible target for cancer specific therapy. However, no LY‐targeting drug is clinically approved yet. We describe in this paper a new therapeutic approach based on alkylation of lysosomal thiols in cancer cells by reversible thiol binder 11 . The treatment with 11 increases the level of lysosomal reactive oxygen species leading to their destabilization, disruption and immunogenic cancer cell death. These effects are not observed in healthy cells. In murine sarcoma Nemeth‐Kellner (NK)/Ly‐RB model, 11 exhibits the spectacular therapeutic effect: it extends the lifespan of the treated mice from 21 to 85 days and cures 40 % of mice. The survived mice develop antibodies against tumor NK/Ly‐RB cells. Their repeated challenge with the NK/Ly‐RB cells results in 100 % mice survival compared to 0 % survival in the control group of naïve mice. Ex vivo data indicate that neutrophils in spleen of the cured animals are also involved in targeting cancer cells and produce neutrophil extracellular traps. In summary, 11 induces the direct antitumor effect supported by humoral immune responses, as well as priming neutrophil's reaction against tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Friedrich-Alexander-University of Erlangen-Nürnberg (FAU), Department of Chemistry and Pharmacy, Organic Chemistry II, 91058, Erlangen, Germany.
- Danylo Halytsky Lviv National Medical University, Department of Histology, Cytology and Embryology, 79010, Lviv, Ukraine.
- Institute of Cellular Biology and Pathology "Nicolae Simionescu", 8 B.P.Hasdeu street, Sector 5, Bucharest, Romania.
ORCID-Profile: Andriy Mokhir
Förderung
- H2020 European Research Council
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Arkhypov, A., Klemt, I., Bila, G., Attia, D., Chernii, S., Bilyy, R., & Mokhir, A. (2025). Targeting Lysosomal Thiols for Immunogenic Cancer Cell Death. Angewandte Chemie International Edition, 64(5). https://doi.org/10.1002/anie.202417509
Vancouver
Arkhypov A, Klemt I, Bila G, Attia D, Chernii S, Bilyy R, et al. Targeting Lysosomal Thiols for Immunogenic Cancer Cell Death. Angewandte Chemie International Edition. 2025;64(5). doi:10.1002/anie.202417509
BibTeX
@article{Arkhypov2025,
author = {Arkhypov, Anton and Klemt, Insa and Bila, Galyna and Attia, Dina and Chernii, Svitlana and Bilyy, Rostyslav and Mokhir, Andriy},
title = {Targeting Lysosomal Thiols for Immunogenic Cancer Cell Death},
journal = {Angewandte Chemie International Edition},
year = {2025},
volume = {64},
number = {5},
doi = {10.1002/anie.202417509}
}
EUVIMED